Table 1.
Patient characteristics by final PACT score
| Characteristic | Final PACT score |
P-value as score increase | |||
|---|---|---|---|---|---|
| Poor (score 0–1, N = 21) | Acceptable (score 2, N = 87) | Good (score 3, N = 177) | Excellent (score 4, N = 119) | ||
| Age in years, median (range) | 46 (22–61) | 50 (21–73) | 50 (18–73) | 49 (19–72) | 0.43 |
| Sex, N (%) | 0.85 | ||||
| Male | 15 (71%) | 40 (46%) | 99 (56%) | 63 (53%) | |
| Female | 6 (29%) | 47 (54%) | 78 (44%) | 56 (47%) | |
| Race, N (%) | 0.004 | ||||
| White | 17 (81%) | 73 (84%) | 158 (89%) | 113 (95%) | |
| Othera | 4 (19%) | 14 (16%) | 19 (11%) | 6 (5%) | |
| Annual household income, median (range) | $46,404 (22,820–95,740) | $49,152 (20,097–112,530) | $48,753 (14,028–100,309) | $53,576 (22,820–100,309) | 0.004 |
| Place of residence, N (%) | 0.38 | ||||
| Urban | 16 (76%) | 68 (78%) | 140 (79%) | 98 (82%) | |
| Rural | 5 (24%) | 19 (22%) | 37 (21%) | 21 (18%) | |
| Karnofsky performance status, median (range)b | 90 (70–100) | 90 (70–100) | 90 (60–100) | 90 (60–100) | 0.010 |
| HCT-CI score, N (%) | 0.007 | ||||
| Low | 4 (19%) | 15 (17%) | 46 (26%) | 42 (35%) | |
| Intermediate | 9 (43%) | 30 (35%) | 61 (34%) | 37 (31%) | |
| High | 8 (38%) | 42 (48%) | 70 (40%) | 40 (34%) | |
| Diagnosis, N (%) | 0.12 | ||||
| AML/MDS | 13 (62%) | 60 (69%) | 98 (55%) | 67 (56%) | |
| Other | 8 (38%) | 27 (31%) | 79 (45%) | 52 (44%) | |
| Disease risk, N (%)b | 0.85 | ||||
| Low | 7 (33%) | 33 (39%) | 82 (49%) | 44 (38%) | |
| Intermediate | 7 (33%) | 18 (21%) | 35 (21%) | 31 (27%) | |
| High | 7 (33%) | 33 (39%) | 49 (30%) | 40 (35%) | |
| Time from diagnosis in months, median (range) | 11 (4–165) | 7 (<1–106) | 7 (1–218) | 7 (1–174) | 0.19 |
| Donor relationship, N (%) | 0.039 | ||||
| Unrelated | 15 (71%) | 48 (55%) | 105 (59%) | 55 (46%) | |
| Related | 6 (29%) | 39 (45%) | 72 (41%) | 64 (54%) | |
| Donor source, N (%) | 0.19 | ||||
| Matched related donor | 6 (29%) | 35 (40%) | 67 (38%) | 61 (51%) | |
| Matched unrelated donor | 12 (57%) | 42 (48%) | 81 (46%) | 46 (39%) | |
| Umbilical cord blood | 3 (14%) | 6 (7%) | 24 (14%) | 9 (8%) | |
| Haploidentical donor | 0 | 4 (5%) | 5 (3%) | 3 (3%) | |
| Graft source, N (%) | 0.84 | ||||
| Bone marrow | 13 (62%) | 52 (60%) | 90 (51%) | 69 (58%) | |
| Peripheral blood | 5 (24%) | 29 (33%) | 63 (36%) | 41 (34%) | |
| Umbilical cord blood | 3 (14%) | 6 (7%) | 24 (14%) | 9 (8%) | |
| CMV serostatus, N (%)b | 0.14 | ||||
| Donor + / recipient + | 7 (33%) | 27 (31%) | 51 (29%) | 33 (28%) | |
| Donor +/ recipient − | 2 (10%) | 11 (13%) | 26 (15%) | 5 (4%) | |
| Donor −/ recipient + | 8 (38%) | 32 (37%) | 59 (34%) | 47 (40%) | |
| Donor −/ recipient − | 4 (19%) | 16 (19%) | 39 (22%) | 32 (27%) | |
| Conditioning regimen, N (%) | 0.46 | ||||
| Myeloablative | 18 (86%) | 73 (84%) | 127 (72%) | 96 (81%) | |
| Reduced intensity | 3 (14%) | 14 (16%) | 50 (28%) | 23 (19%) | |
| FACT-BMT total score, median (range)b | 147 (93–175) | 138 (77–185) | 148 (87–187) | 153 (99–193) | <0.001 |
HCT CI hematopoietic cell transplantation comorbidity index, CMV cytomegalovirus, FACT-BMT functional assessment of cancer therapy-bone marrow transplantation instrument
a
Other ethnic groups included African Americans, Asians, Hispanics, etc
b
Karnofsky performance status was missing in 49 patients; disease risk was not classified in 18 patients; CMV serostatus was missing in 5 patients; FACT BMT quality of life assessments were missing in 34 patients